BUSINESS
Ribomic Confident in Efficacy Outcome of Upcoming PII of Wet-AMD Treatment with Just 40 Patients: Pres.
Yoshikazu Nakamura, president of Ribomic, a nucleic acid drug discovery upstart originated from the University of Tokyo, predicted on May 16 that the company’s investigational anti-FGF2 aptamer RBM-007 will be able to demonstrate its efficacy even in a small-scale PII…
To read the full story
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





